@morgans have an outperform rating on Impedimed (IPD) note from Scott Power follows

Livewire Equities

Livewire

@morgans have an outperform rating on Impedimed (IPD) note from Scott Power follows. Impedimed (IPD, Outperform, Price Target A$0.22) IPD has announced that the American Medical Association (AMA) has made a recommendation to accept the addition of Category I CPT code 937XX2 and delete Category III code 0239T for IPD's device/technology. The decision should become effective from 1 January 2015, which is 12 months earlier than we had expected and is a significant milestone.For those investors with a higher risk profile we suggest buying IPD. Our underlying DCF valuation is A$0.30 and we had set our price target at A$0.22 which we believe will be exceeded today


Livewire Equities
Livewire Equities
Livewire

The Livewire Equities feed brings you a range of insights that relate to Australian equities

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.